NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company • Boehringer Ingelheim (nerandomilast) Patient/carer groups • Action For Pulmonary Fibrosis • Asthma + Lung UK • European Lung Foundation • NARA – The Breathing Charity • Pulmonary Fibrosis Trust • Pulmonary Hypertension Association UK • South Asian Health Foundation • Specialised Healthcare Alliance Healthcare professional groups • Association for Respiratory Technology and Physiology • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Institute of Radiology • British Paediatric Respiratory Society • British Thoracic Society • Interstitial Lung Disease Interdisciplinary Network • National Heart and Lung Institute • Neonatal and Paediatric Pharmacists Group • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Chest, Heart and Stroke Scotland • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Northern Ireland Chest, Heart and Stroke Association • Scottish Medicines Consortium • Welsh Government Possible comparator companies • Amarox (pirfenidone) • Aspen (azathioprine) • Axunio Pharma (pirfenidone) • Baxter Healthcare (cyclophosphamide) • Biogen Biosimilars (infliximab) • Boehringer Ingelheim (nintedanib) • Celix Pharma (pirfenidone) • Celltrion Healthcare (infliximab, rituximab) • Dr Reddy's Laboratories (pirfenidone) • Glenmark Pharmaceuticals Europe (pirfenidone)

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
• Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association <u>Others</u> • Department of Health and Social Care • NHS England	• Janssen-Cilag (infliximab) • Laboratorios Liconsa (pirfenidone) • MSN Laboratories Europe (pirfenidone) • Mylan (azathioprine) • Nova Laboratories (azathioprine) • Novartis Pharmaceuticals (mycophenolate) • Novumgen (pirfenidone) • Pfizer (infliximab, rituximab) • Roche (mycophenolate, pirfenidone, rituximab) • Rosemont Pharmaceuticals (mycophenolate) • Sandoz (azathioprine, infliximab, mycophenolate, pirfenidone, rituximab) • Seacross Pharmaceuticals (cyclophosphamide) • Strides Pharma UK (azathioprine) • Teva UK (mycophenolate, pirfenidone) • Tillomed Laboratories (azathioprine, mycophenolate) <u>Relevant research groups</u> • Asthma, Allergy and Inflammation Research Charity • Breathing Matters • British Association for Lung Research • BRONCH-UK • Cochrane Airways Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

